Morgan Stanley Gemini Therapeutics, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.31 - $2.01 $4,760 - $7,304	-3,634 Reduced 11.73%	27,351 $45,000
Q2 2022 Oct 27, 2022	BUY	$1.22 - $1.73 $40 - $57	33 Added 0.11%	30,985 $53,000
Q2 2022 Aug 15, 2022	BUY	$1.22 - $1.73 $40 - $57	33 Added 0.11%	30,985 $53,000
Q1 2022 Oct 27, 2022	SELL	$1.29 - $3.08 $42 - $101	-33 Reduced 0.11%	30,952 $42,000
Q1 2022 May 13, 2022	BUY	$1.29 - $3.08 $8,387 - $20,026	6,502 Added 26.59%	30,952 $42,000
Q4 2021 Feb 14, 2022	BUY	$2.39 - $4.0 $23,546 - $39,408	9,852 Added 67.49%	24,450 $71,000
Q3 2021 Nov 15, 2021	BUY	$3.3 - $6.32 $48,173 - $92,259	14,598 New	14,598 $58,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.